U.S. Hemophilia Treatment Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (undefined)

U.S. Hemophilia Treatment Market is Segmented By Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Others), By Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The report offers the value (in USD billion) for the above-mentioned segments.

Competitive overview of U.S. Hemophilia Treatment Market

Major players operating in the U.S. hemophilia treatment market include Takeda Pharmaceutical Company Limited., Sanofi Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and  Spark Therapeutics, Inc.

U.S. Hemophilia Treatment Market Leaders

  • Takeda Pharmaceutical Company Limited
  • Sanofi Octapharma AG
  • Swedish Orphan Biovitrum AB
  • Baxter International Inc.
  • Biogen Inc.
*Disclaimer: Major players are listed in no particular order.

U.S. Hemophilia Treatment Market - Competitive Rivalry, 2023

Market Concentration Graph

U.S. Hemophilia Treatment Market

Market Consolidated
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
*Source: Coherent Market Insights